Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer
- 1 July 2003
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 189 (1) , 28-36
- https://doi.org/10.1067/mob.2003.347
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Induction of CA125-Specific B and T Cell Responses in Patients Injected with MAb-B43.13—Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in VivoCancer Biotherapy & Radiopharmaceuticals, 2001
- Anti-idiotype induction therapy: anti-CA125 antibodies (Ab 3 ) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab 1 )Cancer Immunology, Immunotherapy, 1998
- Gene vaccination: plasmid DNA is more than just a blueprintImmunology Today, 1998
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of Clinical Oncology, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Antiidiotype Induction Therapy: Evidence for the Induction of Immune Response through the Idiotype Network in Patients with Ovarian Cancer after Administration of Anti-CA 125 Murine Monoclonal Antibody B43.13Hybridoma, 1995
- Idiotypic antibody immunotherapy of cancerCancer Immunology, Immunotherapy, 1994
- What is an idiotype?Immunology Today, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958